TNF-α Promotes Tumor Lymph Angiogenesis in Head and Neck Squamous Cell Carcinoma Through Regulation of ERK3

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35116996

Authors

Caiyun Zhang

Minhui Zhu

Wei Wang

Donghui Chen

Shicai Chen

Hongliang Zheng

Affiliations

Soon will be listed here.

Abstract

Background: Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common cancer worldwide. The poor prognosis of HNSCC patients is largely due to its early lymph node metastasis. Tumor necrosis factor (TNF)-α has been reported to be involved in lymph angiogenesis in several cancers whereas its relationship with HNSCC was still largely unknown.

Methods: In this work, mice xenograft model was constructed and treated with extra TNF-α, Hep-2 conditioned medium was constructed for human lymphatic endothelial cells (hLECs) culture. qRT-PCR, Western blot analysis and immunohistochemical (IHC) staining were utilized to detect the expression levels of lymph angiogenesis markers as well as ERK3 and its downstream. CCK8 assay was performed to evaluate cell proliferation. Wound healing assay was used for measuring cell migration. Tube formation assay was used to estimate the tube formation ability of hLECs.

Results: The results indicated that TNF-α could up-regulated the expression levels of VEGF-C, VEGFR-3 and LYVE-1 in cell or animal level, change the cell morphology, accelerate cell proliferation, enhance cell migration and tube formation ability of hLECs. Moreover, ERK3 was up-regulated by TNF-α in both cell and animal levels and the over-expression of ERK3 in hLECs could also up-regulate VEGF-C and promote cell proliferation.

Conclusions: In conclusion, this study indicated the promotion effect of TNF-α on tumor lymph angiogenesis in HNSCC and demonstrated that ERK3 may be involved in the underlying molecular mechanism. This work provides new diagnostic and therapeutic targets, which are of great significance to improve the prognosis of HNSCC patients.

Citing Articles

Regulation of VEGFR3 signaling in lymphatic endothelial cells.

Kuonqui K, Campbell A, Pollack B, Shin J, Sarker A, Brown S Front Cell Dev Biol. 2025; 13:1527971.

PMID: 40046235 PMC: 11880633. DOI: 10.3389/fcell.2025.1527971.

Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC.

Meidenbauer J, Wachter M, Schulz S, Mostafa N, Zulch L, Frey B Front Oncol. 2024; 14:1460150.

PMID: 39411143 PMC: 11473424. DOI: 10.3389/fonc.2024.1460150.

Tumor-produced immune regulatory factors as a therapeutic target in cancer treatment.

Rogovskii V Front Immunol. 2024; 15:1416458.

PMID: 39206193 PMC: 11349530. DOI: 10.3389/fimmu.2024.1416458.

Role of the Atypical MAPK ERK3 in Cancer Growth and Progression.

Elkhadragy L, Myers A, Long W Cancers (Basel). 2024; 16(7).

PMID: 38611058 PMC: 11011113. DOI: 10.3390/cancers16071381.

Functional Relevance of Extracellular Vesicle-Derived Long Non-Coding and Circular RNAs in Cancer Angiogenesis.

Pena-Flores J, Muela-Campos D, Guzman-Medrano R, Enriquez-Espinoza D, Gonzalez-Alvarado K Noncoding RNA. 2024; 10(1).

PMID: 38392967 PMC: 10891584. DOI: 10.3390/ncrna10010012.

References

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Long W, Foulds C, Liu J, Ding C, Lonard D, Solis L . ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012; 122(5):1869-80. PMC: 3336992. DOI: 10.1172/JCI61492. View

Cho K, Cheong J, Ha Y, Cho B, Murakami G, Katori Y . The anatomy of fetal peripheral lymphatic vessels in the head-and-neck region: an immunohistochemical study. J Anat. 2011; 220(1):102-11. PMC: 3248668. DOI: 10.1111/j.1469-7580.2011.01441.x. View

Parhar S, Kaur H, Vashist A, Verma S . Role of podoplanin in potentially malignant disorders and oral squamous cell carcinoma and its correlation with lymphangiogenesis. Indian J Cancer. 2016; 52(4):617-22. DOI: 10.4103/0019-509X.178427. View

Sun L, Duan J, Jiang Y, Wang L, Huang N, Lin L . Metastasis-associated in colon cancer-1 upregulates vascular endothelial growth factor-C/D to promote lymphangiogenesis in human gastric cancer. Cancer Lett. 2014; 357(1):242-253. DOI: 10.1016/j.canlet.2014.11.035. View

Pritchard A, Hayward N . Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res. 2013; 19(9):2301-9. DOI: 10.1158/1078-0432.CCR-12-0383. View

Lippitz B . Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013; 14(6):e218-28. DOI: 10.1016/S1470-2045(12)70582-X. View

Keklikoglou I, Hosaka K, Bender C, Bott A, Koerner C, Mitra D . MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene. 2014; 34(37):4867-78. PMC: 4569942. DOI: 10.1038/onc.2014.408. View

Nihei M, Okazaki T, Ebihara S, Kobayashi M, Niu K, Gui P . Chronic inflammation, lymphangiogenesis, and effect of an anti-VEGFR therapy in a mouse model and in human patients with aspiration pneumonia. J Pathol. 2014; 235(4):632-45. DOI: 10.1002/path.4473. View

10.

Kahn H, Marks A . A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002; 82(9):1255-7. DOI: 10.1097/01.lab.0000028824.03032.ab. View

11.

Wang W, Bian K, Vallabhaneni S, Zhang B, Wu R, OMalley B . ERK3 promotes endothelial cell functions by upregulating SRC-3/SP1-mediated VEGFR2 expression. J Cell Physiol. 2014; 229(10):1529-37. PMC: 4078721. DOI: 10.1002/jcp.24596. View

12.

Ishii H, Chikamatsu K, Sakakura K, Miyata M, Furuya N, Masuyama K . Primary tumor induces sentinel lymph node lymphangiogenesis in oral squamous cell carcinoma. Oral Oncol. 2010; 46(5):373-8. DOI: 10.1016/j.oraloncology.2010.02.014. View

13.

Zhang C, Sturgis E, Zheng H, Song X, Wei P, Jin L . Genetic variants in TNF-α promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy. Int J Cancer. 2013; 134(8):1907-15. PMC: 3947426. DOI: 10.1002/ijc.28512. View

14.

Al-Mahdi R, Babteen N, Thillai K, Holt M, Johansen B, Wetting H . A novel role for atypical MAPK kinase ERK3 in regulating breast cancer cell morphology and migration. Cell Adh Migr. 2015; 9(6):483-94. PMC: 4955959. DOI: 10.1080/19336918.2015.1112485. View

15.

Bouta E, Wood R, Brown E, Rahimi H, Ritchlin C, Schwarz E . In vivo quantification of lymph viscosity and pressure in lymphatic vessels and draining lymph nodes of arthritic joints in mice. J Physiol. 2014; 592(6):1213-23. PMC: 3961082. DOI: 10.1113/jphysiol.2013.266700. View

16.

Han K, Chang J, Dugas-Ford J, Alexander J, Azar D . Involvement of lysosomal degradation in VEGF-C-induced down-regulation of VEGFR-3. FEBS Lett. 2014; 588(23):4357-63. PMC: 4254303. DOI: 10.1016/j.febslet.2014.09.034. View

17.

Gordon E, Gale N, Harvey N . Expression of the hyaluronan receptor LYVE-1 is not restricted to the lymphatic vasculature; LYVE-1 is also expressed on embryonic blood vessels. Dev Dyn. 2008; 237(7):1901-9. DOI: 10.1002/dvdy.21605. View

18.

Zhang C, Sturgis E, Zheng H, Zafereo M, Wei Q, Li G . TNF-α promoter polymorphisms and risk of recurrence in patients with squamous cell carcinomas of the nonoropharynx. Int J Cancer. 2014; 135(7):1615-24. PMC: 4107187. DOI: 10.1002/ijc.28793. View

19.

Stacker S, Williams S, Karnezis T, Shayan R, Fox S, Achen M . Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer. 2014; 14(3):159-72. DOI: 10.1038/nrc3677. View

20.

Cha H, Bae E, Koh J, Chai J, Jeon C, Ahn K . Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes. J Rheumatol. 2007; 34(1):16-9. View